What Can Recover, What Is Irreversible

Core Concept: Function vs Structure

To understand the reversibility of riñón injury, first distinguish two concepts:

• Functional suppression: Cells and tejidos temporarily "stop working," but structure is intact. After removing the suppressing factor, function can recover.
• Structural damage: Cell death, tejido replaced by fibrosis, vessel occlusion. This damage is typically irreversible.

This distinction is crucial for ADPKD pacientes — it explains why función renal can improve in some situations but not others.

Reversible: Functional Suppression

Drug-Induced Hemodynamic Changes

ACEI/ARB lower glomerular internal pressure, potentially causing slight eGFR decline at tratamiento start (usually 10-15%). This is functional suppression — glomerular filtración pressure is reduced, but nefrona structure is intact. eGFR rebounds after stopping the drug. This initial decline is not riñón damage — it's a sign the drug is working.

Similarly, NSAIDs constrict afferent arterioles, reversibly lowering GFR. Usually recovers after stopping — but long-term use may cause ischemic damage, becoming irreversible.

Hypovolemia

Dehydration, excessive diuresis, hemorrhage causing hypovolemia reduces renal perfusion and GFR. This is functional suppression — función renal recovers after fluid replacement. But if severe hypoperfusion persists, it can progress to acute tubular necrosis, becoming structural damage.

Early Stages of Acute Kidney Injury (AKI)

In early AKI, tubular células may be in a "stunned" state — células survive but function is suppressed. If the cause is promptly removed (restoring perfusion, stopping nephrotoxins), these células can recover function. But if injury persists, células undergo apoptosis or necrosis, becoming irreversible.

Early Cyst Compression

Early quiste compression of surrounding túbulos may be functional — túbulos are compressed closed but células survive. If quistes shrink (e.g., tolvaptán reducing quiste volume), some tubular function may recover. This is why tolvaptán better preserves eGFR in early pacientes — intervening before structural damage occurs.

Hypertension-Induced Glomerular Hypertension

Glomerular hipertensión is functional in early estadios — controlling presión arterial restores glomerular internal pressure and improves filtración. HALT-PKD confirmed that strict BP control (110/75) better slows TKV growth than standard control (130/80). But long-term hipertensión leads to glomerulosclerosis and interstitial fibrosis, becoming irreversible.

Irreversible: Structural Damage

Tubular Atrophy

When quistes chronically compress túbulos, or ischemia persists, tubular epithelial células undergo apoptosis and senescence, túbulo diameter shrinks, eventually atrophying and occluding. Atrophied túbulos cannot regenrate — this is the core structural damage of ADPKD función renal loss.

Tubular atrophy is a key marker of CKD progresión, predicting eGFR decline better than glomerular pathology. Once it occurs, no current tratamiento can reverse it.

Interstitial Fibrosis

Ischemia and inflamación activate interstitial fibroblasts, transforming them into myofibroblasts that secrete large amounts of collagen and extracélulaular matrix, replacing normal renal interstitium. Fibrotic tejido is permanent — no drug can eliminate formed fibrosis (though investigación is exploring anti-fibrotic tratamientos).

Fibrosis also causes peritubular capillary rarefaction (capillary loss), worsening ischemia and creating a vicious cycle. Once started, this cycle may self-propagate even if the original cause (crecimiento de quistes) is stopped.

Glomerulosclerosis

Long-term hipertensión and hyperfiltración cause glomerular capillary loop collapse and mesangial matrix proliferación, forming focal segmental glomerulosclerosis (FSGS). Sclerotic glomérulos permanently lose filtración function. This is why presión arterial control is so important — preventing irreversible glomerular damage.

Atubular Glomeruli

When the túbulo connecting to a glomérulo atrophies and occludes, the glomérulo loses its outflow pathway, becoming an "atubular glomérulo" — although the glomérulo itself may appear normal, it efectivoly loses function because no túbulo receives the filtrate. This damage is irreversible.

Aristolochic Acid Nephropathy

Aristolochic acid-induced riñón damage is progresivo and irreversible. Aristolochic acid enters proximal tubular células via órganoic anion transporters (OAT1/OAT3), forms DNA adducts, causing A→T mutacións, apoptosis, and interstitial fibrosis. Even after exposure stops, damage may continue progressing. No efectivo tratamiento exists.

This is why avoiding ácido aristolóquico-containing herbs is so important — prevención is the only protection.

AKI to CKD Transition: Maladaptive Repair

After AKI, some pacientes progress to enfermedad renal crónica even after the original cause is removed. The mechanism is maladaptive repair:

1. Dedifferentiation and proliferación: After AKI, surviving epithelial células dedifferentiate and proliferate to repair túbulos.
2. G2/M célula cycle arrest: Some proliferating células stall at G2/M phase, unable to complete division and redifferentiation.
3. Senescent célula accumulation: G2/M-arrested células become senescent, secreting pro-fibrotic factors (SASP).
4. Pro-fibrotic microenvironment: Senescent célula factors activate fibroblasts and pericytes, forming myofibroblasts.
5. Capillary rarefaction: Peritubular capillary endothelial célula damage and loss, worsening ischemia.
6. Self-propagating fibrosis: Even after removing the original injury, the fibrotic microenvironment self-maintains, causing progresivo fibrosis.

For ADPKD, this means: if AKI occurs (quiste hemorrhage, infection, stone obstruction, contrast nephropathy), it not only acutely damages función renal but may accelerate long-term CKD progresión through maladaptive repair. Therefore preventing AKI is especially important for ADPKD pacientes.

Why eGFR Decline "Suddenly" Accelerates

ADPKD pacientes often notice eGFR "suddenly" starts declining rapidly after years of stability. This isn't sudden — it's the result of structural damage accumulating to a critical point:

1. Early: Cysts grow, but normal nefronas compensate, eGFR remains normal.
2. Mid: Cyst compression and ischemia cause some nefrona atrophy and fibrosis, but remaining nefronas hyperfiltrate to compensate, eGFR slowly declines.
3. Critical point: When lost nefronas exceed compensatory capacity, eGFR begins to decline noticeably.
4. Late: Fibrosis vicious cycle initiates, eGFR rapidly declines.

This is why TKV growth precedes eGFR decline — structural damage accumulates for years before functional decline. Also why early intervention (before the critical point) is more efectivo than late intervention.

Tolvaptan's Lesson: Early vs Late Intervention

Tolvaptan ensayo clínicos provide important insights about reversibility:

• TEMPO 3:4 (early pacientes, eGFR >60): Tolvaptan significantly slowed TKV growth and eGFR decline. Best effect when intervening with less structural damage.
• REPRISE (mid-late pacientes, eGFR 25-60): Tolvaptan slowed eGFR decline, but less efectivoly than in early disease. Limited beneficio with more structural damage.

This confirms the principle that structural damage is irreversible — tolvaptán can slow future damage but cannot repair existing fibrosis and atrophy. Early identification of rapid progressors and early intervention is key to preserving función renal.

Limits of Nephron Compensation

When some nefronas are lost, remaining nefronas compensate through hyperfiltración — single-nefrona GFR increases to maintain total GFR. But this compensation has costs:

• Hyperfiltración increases glomerular internal pressure and mechanical estrés.
• Long-term hyperfiltración leads to glomerulosclerosis and further nefrona loss.
• Creates a "nefrona loss → hyperfiltración → sclerosis → more loss" vicious cycle.

ACEI/ARB reduce glomerular internal pressure, mitigating hyperfiltración injury and breaking this cycle. This is their core renoprotective mechanism, and why all ADPKD hipertensión pacientes should use ACEI or ARB.

Practical Implications: How You Should Act

Intervene Before Structural Damage

• Regularly monitor TKV and eGFR — understand your disease progresión speed.
• Control presión arterial early — prevent glomerulosclerosis and interstitial fibrosis.
• Early tolvaptán for rapid progressors — intervene while structural damage is still reversible.
• Avoid nephrotoxins and AKI — prevent irreversible damage.

When Structural Damage Already Exists

• Don't give up — slowing future damage still has value.
• Strictly control presión arterial and estilo de vida factors.
• Discuss with your doctor whether tolvaptán is appropriate (even in late estadio, it can slow residual eGFR decline).
• Prepare for terapia de reemplazo renal — understand diálisis and trasplante options.

Understanding Test Result Fluctuations

• A single eGFR decline isn't necessarily structural damage — may be functional suppression (dehydration, medicamentos, AKI).
• Focus on long-term trends rather than single values.
• Slight eGFR rebound (e.g., after stopping ACEI) is functional recovery, not structural repair.
• Continued TKV growth with stable eGFR doesn't mean seguridad — structural damage is accumulating.

Future Hope: Anti-Fibrotic Therapies

No approved anti-fibrotic tratamientos exist yet, but investigación is exploring multiple targets:

• Anti-TGF-β therapy (TGF-β is the core fibrosis factor).
• Senolytics — clearing G2/M-arrested senescent células.
• Pro-regenrative therapy — stimulating tubular epithelial regenration (currently mainly in animal estadios).

These tratamientos remain in investigación estadios and should not be attempted without medical guidance. But they offer hope for future fibrosis reversal.

← Back to Mechanism